KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)
Authors
Hoimes, C. J.Graff, J. N.
Tagawa, S. T.
Hwang, C.
Kilari, D.
Ten Tije, A. J.
Omlin, A.
McDermott, R. S.
Vaishampayan, U. N.
Elliott, Tony
Gerritsen, W. R.
Wu, H. Y.
Kim, J.
Schloss, C.
De Bono, J. S.
Antonarakis, E. S.
Affiliation
Duke Cancer Institute, Durham, NC;Issue Date
2020